Radiation Toxicity Treatment Market Outlook To 2024: Key Exposure Type (Acute radiation syndrome, Chronic Radiation Syndrome), Radiation Type (Ionizing, Non-Ionizing), Disease Type, Treatment Type, Regional Segmentation, Pipeline Analysis, Regulatory Landscape, Competitive Dynamics, M&A Insights, Segment Forecast And Conclusion

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.

 

Industry at a Glance

 

Rising tension and missile warfare at Korean peninsula putting world at crossroad of possible dangerous nuclear disaster. A 10-kiloton detonation to city population like Virginia (with a population of 2 million) can bring more than 270,000 Acute Radiation Syndrome incidents. Hence major federal governments of the world are keeping them prepared for the treatment.

 

Some of the leading players in the market have been assessed using three major parameters such as Product portfolio, Government funding and Market Dominance. In addition, few other parameters considered include financials, technological advancements and product reviews from end users. Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services.  Their range of products developed has application from Acute Radiation Syndrome to Nerve gas exposure.

 

Global Radiation Toxicity Market 2024

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Radiation Toxicity Treatment Products”

 

Estimated Average Acute Radiation Syndrome Treatment cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

The pricing strategies being adopted by industry participants is largely influenced by factors such as R&D costs, government funding and demand in the market. Technological advancements in the field of Biologics will also play an important role in shaping pricing trends in the market over the forecast period.

 

Type Outlook

 

Based on the radiation type, the market has been segmented into ionizing and non-ionizing. The market is further segmented by disease and treatment type. Based on type of exposure, market is segmented to Acute and Chronic Radiation Syndrome. Market is dominated by Acute Radiation Syndrome. By disease type, G.I syndrome contributes maximum % to overall revenue. By treatment type, Bone marrow transplant represents the maximum % to overall revenue.

Application Outline

 

Acute exposure to ionizing radiation triggers apoptotic cell death of hematopoietic stem and progenitor cells (HSPCs), leaving the individual prone to infection and hemorrhage. Therefore, the administration of antiapoptotic cytokines and colony-stimulating factors represents an important aspect of treatment of a patient with acute radiation syndrome. Transfusion of whole blood or peripheral blood mononuclear cells delivering myeloid progenitor cells has been proposed as a “bridging therapy” in patients who have suffered a severe but not complete injury to the hematopoietic system. Transplanted progenitor cells might provide the necessary granulocytes, red blood cells and platelets during the critical period of bone marrow failure.

 

Pipeline Analysis

 

We have detail pipeline analysis in the report including drug name, Organization, Mechanism of action and Status. There are different theories propounded regarding the mechanisms of radiation protection, such as free radical scavenging, calcium channel blocking, inhibition of lipid peroxidation, enhancement of DNA repair and stimulation of stem cell proliferation are considered important.

Overall R&D activities revolve around-

  • Prophylactics
  • Mitigators
  • Treatment

Clinical testing of potential Radioprotective Agents could be initiated only after the radioprotective efficacy is convinced by preclinical studies that simulate, as much as possible, the conditions under which the agent will be used clinically.

 

Regional Segmentation

 

U.S being the largest market because of its sensitive military activities and threat perception. It accounted for xx % of the market share in 2016 ($ x,xxx Million) and will keep growing to occupy 54% of the global market. Middle East market in decline trend due to moving out of U.S troops and reducing threat perception. In Europe, UK, Germany, France represent significant market

 

In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.

 

Growth Drivers & Restraints

 

Some of the leading market drivers are Nuclear Attack Threat Perception, Increasing Use of Radiation Therapy, Nuclear Medicine in the Treatment and Diagnosis of Diseases and Increasing Government Support for Research and Development. Key market challenges are High Cost of Treatment, Shortage of Trained Professional and Accessibility of Treatment.

 

Top Players & Company Share

 

Prominent companies operating in the global chiral chromatography columns market include Osiris Therapeutics Inc., Nanotherapeutics Inc., NeoStem Inc., Gamida Cell Ltd, Cantex Pharmaceuticals Inc., Aeolus Pharmaceuticals, Cleveland BioLabs Inc., Tonix Pharmaceuticals Holding Corp, Onconova Therapeutics Inc.

 

Market Segmentation

 

Radiation Toxicity Treatment Market by “Type of Exposure” (Revenue, USD Million, 2014- 2024)

  • Acute radiation syndrome (ARS) (Single large exposure)
  • Chronic Radiation Syndrome (Small exposures spread over time)

Radiation Toxicity Treatment Market by “Radiation Type” (Revenue, USD Million, 20124- 2024)

  • Ionizing (Alpha/Beta/Gama)
  • Non-Ionizing

Radiation Toxicity Treatment Market by “Disease Type” (USD Million) (Revenue, USD Million, 20124- 2024)

  • Bone Marrow Syndrome (Hematopoietic)
  • Gastrointestinal Syndrome (GI)
  • Cardiovascular (CV)
  • Central Nervous System (CNS) Syndrome

Radiation Toxicity Treatment Market Regional Outlook (Revenue, USD Million, 20124- 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Latin America
    • Brazil
    • Mexico
    • Colombia
  • Asia pacific
    • Korea
    • Japan
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa

 

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Radiation Toxicity Treatment Market Overview

  • Disease Landscape
  • Healthcare Expenditure

Chapter 4 Radiation Toxicity Treatment Market Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Major Buying Authorities and Decision-Making Process
  • Key Market Drivers
    • Increasing use of radiation therapy
    • Nuclear medicine in the treatment and diagnosis of diseases
    • Increasing Government Support for Research and Development
  • Key Market Challenges
    • High Cost of Treatment
    • Shortage of Trained Professionals
    • Accessibility of Treatment
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Radiation Toxicity Market-PESTEL Analysis

Chapter 5: - Radiation Toxicity Treatment Market by “Type of Exposure” (USD Million)

  • Radiation Toxicity Treatment Market Landscape by Exposure Type- 2016 & 2024
    • Acute radiation syndrome (ARS) (Single large exposure)
  • Market Landscape Analysis, 2016-2024 (USD Mn)
    • Chronic Radiation Syndrome (Small exposures spread over time)
  • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 6: - Radiation Toxicity Treatment Market by “Radiation Type” (USD Million)

Radiation Toxicity Treatment Market Landscape by Radiation Type- 2016 & 2024
  • Ionizing (Alpha/Beta/Gama)
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Non-Ionizing
    • Market Landscape Analysis, 2016-2024 (USD Mn)
 

Chapter 7: - Radiation Toxicity Treatment Market by “Disease Type” (USD Million)

Radiation Toxicity Treatment Market Landscape by Disease Type- 2016 & 2024
  • Bone Marrow Syndrome (Hematopoietic)
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Gastrointestinal Syndrome (GI)
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Cardiovascular (CV)
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Central Nervous System (CNS) Syndrome
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 8: - Radiation Toxicity Treatment Market by “Treatment Type” (USD Million)

Radiation Toxicity Treatment Market Landscape by Treatment Type- 2016 & 2024
  • Antibiotics
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Blood products
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Colony Stimulating Factors
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Bone marrow transplant
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Stem cell transplant
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Blood/platelet transfusions
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 9: Regional Market Outlook

Radiation Toxicity Treatment Market Landscape by Region- 2016
  • North America Market Landscape Analysis, 2016-2024 (USD Mn)
    • U.S. Market Landscape Analysis, 2016-2024
    • Canada Market Landscape Analysis-2016-2024
  • Europe Market Landscape Analysis, 2016-2024 (USD Mn)
    • UK Market Landscape Analysis, 2016-2024
    • Germany Market Landscape Analysis, 2016-2024
    • France Market Landscape Analysis, 2016-2024
    • Italy Market Landscape Analysis, 2016-2024
    • Spain Market Landscape Analysis, 2016-2024
  • Latin America Market Landscape Analysis, 2016-2024 (USD Mn)
    • Brazil Market Landscape Analysis, 2016-2024
    • Mexico Market Landscape Analysis, 2016-2024
    • Colombia Market Landscape Analysis, 2016-2024
  • Asia pacific Market Landscape Analysis, 2016-2024 (USD Mn)
    • Korea Market Landscape Analysis, 2016-2024
    • Japan Market Landscape Analysis, 2016-2024
    • China Market Landscape Analysis, 2016-2024
    • India Market Landscape Analysis, 2016-2024
  • Middle East & Africa Market Landscape Analysis, 2014-2024 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2024
    • South Africa Market Landscape Analysis, 2014-2024
 

Chapter 10: Pricing Analysis

Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2016
  • North America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • U.S. Pricing Analysis-2016
    • Canada Pricing Analysis-2016
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2016)
    • UK Pricing Analysis-2016
    • Germany Pricing Analysis-2016
    • France Pricing Analysis-2016
    • Italy Pricing Analysis-2016
    • Spain Pricing Analysis-2016
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Brazil Pricing Analysis-2016
    • Mexico Pricing Analysis-2016
    • Colombia Pricing Analysis-2016
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Korea Pricing Analysis-2016
    • Japan Pricing Analysis-2016
    • China Pricing Analysis-2016
    • India Pricing Analysis-2016
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Saudi Arabia Pricing Analysis-2016
    • South Africa Pricing Analysis-2016

Chapter 11: Radiation Toxicity Treatment Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 12: Radiation Toxicity Treatment Merger & Acquisition Outlook

  • Major licensing deals
  • Factors driving M&A in Radiation Toxicity market
  • Key trends and future outlook

Chapter 13: Radiation Toxicity Treatment Regulatory & Patent Outlook

  • Regulatory Landscape by Region (U.S., Europe, and RoW)
  • Patent Landscape by Region (U.S., Europe, and RoW)

Chapter 14: Competitive Landscape 

  • Osiris Therapeutics Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Nanotherapeutics Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • NeoStem Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Gamida Cell Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Cantex Pharmaceuticals Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Aeolus Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Cleveland BioLabs Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Piramal Enterprises Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Tonix Pharmaceuticals Holding Corp
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Onconova Therapeutics Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  List of Tables  
  • TABLE 1 Radiation Toxicity Market - Industry Snapshot & Key Buying Criteria, 2014 - 2024
  • TABLE 2 Global Radiation Toxicity Market, 2014 – 2024
  • TABLE 3 Global Radiation Toxicity Market Analysis by Product-2016
  • TABLE 4 Global Radiation Toxicity Market Analysis by Technology -2016
  • TABLE 5 Global Radiation Toxicity Market Analysis by Application-2016
  • TABLE 7 Global Radiation Toxicity Market Analysis by Geography-2016
  • TABLE 8 Global Radiation Toxicity Market Analysis by Leading Brands-2016
  • TABLE 9 Radiation Toxicity Market - Key market driver analysis
  • TABLE 10 Radiation Toxicity Market - Key market restraint analysis
  • TABLE 11 North America Market Radiation Toxicity Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 12U.S. Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 13 Canada Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 14 Europe Radiation Toxicity Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 15 U.K Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 16 Germany Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 17 France Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 18 Italy Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 19 Spain Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 20 Latin America Radiation Toxicity Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 21 Brazil Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 22 Mexico Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 20 Colombia Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 21 Asia pacific Radiation Toxicity Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 22 Japan Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 23 China Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 24 India Radiation Toxicity Market Landscape Analysis, 2016-2024
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 27 U.S. Pricing Analysis-2016
  • TABLE 28 Canada Pricing Analysis-2016
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 30 U.K Pricing Analysis-2016
  • TABLE 31 Germany Pricing Analysis-2016
  • TABLE 32 France Pricing Analysis-2016
  • TABLE 33 Italy Pricing Analysis-2016
  • TABLE 34 Spain Pricing Analysis-2016
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 36 Brazil Pricing Analysis-2016
  • TABLE 37 Mexico Pricing Analysis-2016
  • TABLE 38 Colombia Pricing Analysis-2016
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 40 Japan Pricing Analysis-2016
  • TABLE 41 China Pricing Analysis-2016
  • TABLE 42 India Pricing Analysis-2016
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 44 Saudi Arabia Pricing Analysis-2016
  • TABLE 45 South Africa Pricing Analysis-2016
  List of Figures  
  • 1 Radiation Toxicity Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Radiation Toxicity Market – PESTEL Analysis
  • 7 Radiation Toxicity Market Share by Product Type, 2016 & 2024
  • 8 Radiation Toxicity Market Share by Technology Type, 2016 & 2024
  • 9 Radiation Toxicity Market Share by Application Type, 2016 & 2024
  • 10 Radiation Toxicity Market Share by Region, 2016 & 2024

Key Insights Addressed:  

  • Defining market size from 2014 to 2016.
  • Estimating market growth till 2024 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:  
  • The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.
  • Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services.
  • In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.
  • key market players include Agilent Technologies, Waters Corporation, Phenomenex Inc., Sartorius AG, Daicel Corporation, Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, Shimadzu Corporation, GE Healthcare, W.R. Grace, and Regis Technologies.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involve in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.

 

Industry at a Glance

 

Rising tension and missile warfare at Korean peninsula putting world at crossroad of possible dangerous nuclear disaster. A 10-kiloton detonation to city population like Virginia (with a population of 2 million) can bring more than 270,000 Acute Radiation Syndrome incidents. Hence major federal governments of the world are keeping them prepared for the treatment.

 

Some of the leading players in the market have been assessed using three major parameters such as Product portfolio, Government funding and Market Dominance. In addition, few other parameters considered include financials, technological advancements and product reviews from end users. Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services.  Their range of products developed has application from Acute Radiation Syndrome to Nerve gas exposure.

 

Global Radiation Toxicity Market 2024

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Radiation Toxicity Treatment Products”

 

Estimated Average Acute Radiation Syndrome Treatment cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

The pricing strategies being adopted by industry participants is largely influenced by factors such as R&D costs, government funding and demand in the market. Technological advancements in the field of Biologics will also play an important role in shaping pricing trends in the market over the forecast period.

 

Type Outlook

 

Based on the radiation type, the market has been segmented into ionizing and non-ionizing. The market is further segmented by disease and treatment type. Based on type of exposure, market is segmented to Acute and Chronic Radiation Syndrome. Market is dominated by Acute Radiation Syndrome. By disease type, G.I syndrome contributes maximum % to overall revenue. By treatment type, Bone marrow transplant represents the maximum % to overall revenue.

Application Outline

 

Acute exposure to ionizing radiation triggers apoptotic cell death of hematopoietic stem and progenitor cells (HSPCs), leaving the individual prone to infection and hemorrhage. Therefore, the administration of antiapoptotic cytokines and colony-stimulating factors represents an important aspect of treatment of a patient with acute radiation syndrome. Transfusion of whole blood or peripheral blood mononuclear cells delivering myeloid progenitor cells has been proposed as a “bridging therapy” in patients who have suffered a severe but not complete injury to the hematopoietic system. Transplanted progenitor cells might provide the necessary granulocytes, red blood cells and platelets during the critical period of bone marrow failure.

 

Pipeline Analysis

 

We have detail pipeline analysis in the report including drug name, Organization, Mechanism of action and Status. There are different theories propounded regarding the mechanisms of radiation protection, such as free radical scavenging, calcium channel blocking, inhibition of lipid peroxidation, enhancement of DNA repair and stimulation of stem cell proliferation are considered important.

Overall R&D activities revolve around-

  • Prophylactics
  • Mitigators
  • Treatment

Clinical testing of potential Radioprotective Agents could be initiated only after the radioprotective efficacy is convinced by preclinical studies that simulate, as much as possible, the conditions under which the agent will be used clinically.

 

Regional Segmentation

 

U.S being the largest market because of its sensitive military activities and threat perception. It accounted for xx % of the market share in 2016 ($ x,xxx Million) and will keep growing to occupy 54% of the global market. Middle East market in decline trend due to moving out of U.S troops and reducing threat perception. In Europe, UK, Germany, France represent significant market

 

In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.

 

Growth Drivers & Restraints

 

Some of the leading market drivers are Nuclear Attack Threat Perception, Increasing Use of Radiation Therapy, Nuclear Medicine in the Treatment and Diagnosis of Diseases and Increasing Government Support for Research and Development. Key market challenges are High Cost of Treatment, Shortage of Trained Professional and Accessibility of Treatment.

 

Top Players & Company Share

 

Prominent companies operating in the global chiral chromatography columns market include Osiris Therapeutics Inc., Nanotherapeutics Inc., NeoStem Inc., Gamida Cell Ltd, Cantex Pharmaceuticals Inc., Aeolus Pharmaceuticals, Cleveland BioLabs Inc., Tonix Pharmaceuticals Holding Corp, Onconova Therapeutics Inc.

 

Market Segmentation

 

Radiation Toxicity Treatment Market by “Type of Exposure” (Revenue, USD Million, 2014- 2024)

  • Acute radiation syndrome (ARS) (Single large exposure)
  • Chronic Radiation Syndrome (Small exposures spread over time)

Radiation Toxicity Treatment Market by “Radiation Type” (Revenue, USD Million, 20124- 2024)

  • Ionizing (Alpha/Beta/Gama)
  • Non-Ionizing

Radiation Toxicity Treatment Market by “Disease Type” (USD Million) (Revenue, USD Million, 20124- 2024)

  • Bone Marrow Syndrome (Hematopoietic)
  • Gastrointestinal Syndrome (GI)
  • Cardiovascular (CV)
  • Central Nervous System (CNS) Syndrome

Radiation Toxicity Treatment Market Regional Outlook (Revenue, USD Million, 20124- 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Latin America
    • Brazil
    • Mexico
    • Colombia
  • Asia pacific
    • Korea
    • Japan
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa

 

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650